Secondary Progressive Multiple Sclerosis (SPMS)

Neurology
1
Pipeline Programs
1
Companies
7
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Novartis
MAYZENTApproved
siponimod
Novartis
Sphingosine 1-phosphate Receptor Modulator [EPC]oral2019

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
MAYZENT(Mayzent)N/A5 trials
Active Trials
NCT06395909Completed113Est. Aug 2023
NCT05376579Completed134Est. Jul 2025
NCT04933552Recruiting867Est. May 2032
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
NovartisMayzent
NovartisMayzent
NovartisMayzent
NovartisMayzent
NovartisMayzent
NovartisMayzent
NovartisMayzent

Clinical Trials (7)

Total enrollment: 2,126 patients across 7 trials

NCT03623243NovartisMayzent

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Start: Feb 2019Est. completion: Jul 2022185 patients
Phase 3Completed
NCT06395909NovartisMayzent

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

Start: Apr 2023Est. completion: Aug 2023113 patients
N/ACompleted
NCT05376579NovartisMayzent

Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

Start: Jun 2022Est. completion: Jul 2025134 patients
N/ACompleted
NCT04933552NovartisMayzent

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

Start: Dec 2021Est. completion: May 2032867 patients
N/ARecruiting
NCT04895202NovartisMayzent

Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

Start: Nov 2021Est. completion: Dec 20228 patients
N/ATerminated
NCT04593927NovartisMayzent

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

Start: Oct 2020Est. completion: Aug 2023451 patients
N/ACompleted
NCT05826028NovartisMayzent

Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

Start: Jul 2020Est. completion: Apr 2022368 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
11h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
11h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
11h ago

Director of Finance

CoMind
London, UK
11h ago

Electronics Engineering Manager

CoMind
London, UK
11h ago

Director of Information Technology

Zavation Medical Products
11h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 2,126 patients
1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)